$3.03 Million is the total value of Camber Capital Management LP's 40 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 23.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | Sell | VIATRIS INC | $197,200 | -12.2% | 20,000,000 | -11.1% | 6.50% | -11.1% |
| SNY | Sell | SANOFIsponsored adr | $147,510 | -31.6% | 2,750,000 | -31.2% | 4.86% | -30.8% |
| WBA | Sell | WALGREENS BOOTS ALLIANCE INC | $115,648 | -45.9% | 5,200,000 | -30.7% | 3.81% | -45.2% |
| Sell | GSK PLCsponsored adr | $103,313 | -29.3% | 2,850,000 | -30.5% | 3.40% | -28.4% | |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $102,060 | -0.5% | 2,250,000 | -10.0% | 3.36% | +0.7% |
| SEM | Sell | SELECT MED HLDGS CORP | $85,918 | -33.4% | 3,400,000 | -16.0% | 2.83% | -32.6% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $65,340 | +0.5% | 1,500,000 | -16.7% | 2.15% | +1.7% |
| PRGO | Sell | PERRIGO CO PLC | $59,108 | -30.4% | 1,850,000 | -26.0% | 1.95% | -29.5% |
| QTRX | Sell | QUANTERIX CORP | $34,604 | -55.2% | 1,275,000 | -62.8% | 1.14% | -54.6% |
| EXEL | Sell | EXELIXIS INC | $6,555 | -77.9% | 300,000 | -80.6% | 0.22% | -77.6% |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -300,000 | -100.0% | -0.13% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -160,000 | -100.0% | -0.37% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -400,000 | -100.0% | -0.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.